AB 888: Opioid prescriptions: information: nonpharmacological treatments for pain.
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2019-04-11
|
Date
|
Status
|
|---|---|
| Jul 1, 2019 | In committee: Testimony taken. Hearing postponed by committee. |
| Jun 6, 2019 | In committee: Hearing postponed by committee. |
| May 22, 2019 | Referred to Coms. on B., P. & E.D. and HEALTH. |
| May 9, 2019 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 9, 2019 | Read third time. Passed. Ordered to the Senate. |
| May 2, 2019 | Read second time. Ordered to third reading. |
| May 1, 2019 | From committee: Do pass. (Ayes 15. Noes 0.) (May 1). |
| Apr 22, 2019 | Re-referred to Com. on APPR. |
| Apr 11, 2019 | Read second time and amended. |
| Apr 10, 2019 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 15. Noes 0.) (April 9). |
| Apr 2, 2019 | From committee: Do pass and re-refer to Com. on HEALTH. (Ayes 17. Noes 0.) (April 2). Re-referred to Com. on HEALTH. |
| Mar 25, 2019 | Re-referred to Com. on HEALTH. |
| Mar 21, 2019 | Referred to Coms. on HEALTH and B. & P. |
| Feb 21, 2019 | From printer. May be heard in committee March 23. |
| Feb 20, 2019 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| May 9, 2019 | AB 888 Low Assembly Third Reading | Assembly Floor |
Passed |
|
| May 1, 2019 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 9, 2019 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
|
| Apr 2, 2019 | Do pass and be re-referred to the Committee on [Health] | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Steven Glazer, Chair
2019 - 2020 Regular
Bill No: Hearing Date: July 1, 2019
Author: | |||
Version: | April 11, 2019 | ||
Urgency: | No | Fiscal: | Yes |
Consultant: | Sarah Mason | ||
Subject:
SUMMARY:
Expands requirements for prescribers to discuss risks and dangers of opioids and opioid addiction to all patients and adds a requirement that the prescriber discuss the availability of nonpharmacological treatments for pain. Requires a prescriber to obtain informed written consent for an opioid prescription and offer the patient a referral for a provider of nonpharmacological treatments for pain. Includes services offered by a number of licensed professionals in the definition of nonpharmacological treatments for pain.
NOTE:
This bill is referred, second, to the Senate Committee on Health.
Existing law:
- Establishes various practice acts in the Business and Professions Code (BPC) governed by various boards within the Department of Consumer Affairs (DCA) which provide for the licensing and regulation of health care professionals. (Business and Professions Code (BPC) § 500 et seq.)
- Requires that existing trainings for certain health care professionals related to pain management include addiction risks associated with Schedule II drugs.
- Prohibits any person other than a physician, dentist, podiatrist, veterinarian, naturopathic doctor (ND) (according to certain supervision and protocol requirements), pharmacist (according to certain authorizations, policies and procedures), certified nurse-midwife (CNM) (if furnished or ordered incidentally to the provision of family planning services, routine health care or perinatal care, or care rendered consistent with the CNM’s practice; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified), nurse practitioner (NP) (if it is consistent with a NP’s educational preparation or for which clinical competency has been established and maintained; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified); a pharmacist or registered nurse or physician’s assistant (PA) acting within the scope of an experimental health workforce project authorized by the Office of Statewide Health Planning and Development (Health and Safety Code (HSC) § 128125 et seq.); an optometrist licensed under the Optometry Practice Act, or an out-of-state prescriber acting in an emergency situation from writing or issuing a prescription for a controlled substance. (HSC § 11150)
- Defines a controlled substance as any substance listed in Uniform Controlled Substances Act. (BPC § 4021)
- Establishes schedules of drugs, from I – V, under the Uniform Controlled Substances Act, in descending order of the potential for abuse. (HSC §§ 11053 et seq)
- Specifies that a prescription for a controlled substance shall only be issued for a legitimate medical purpose and establishes responsibility for proper prescribing on the prescribing practitioner. States that a violation shall result in imprisonment for up to one year or a fine of up to $20,000, or both. (HSC § 11153)
- Requires a prescriber, for minor patients, prior to directly dispensing or issuing a prescription for a controlled substance containing an opioid, to discuss information, including the risks of addiction and overdose associated with the use of opioids, the increased risk of addiction to an individual who is suffering from both mental and substance abuse disorders, and the danger of taking an opioid with a benzodiazepine, alcohol, or another central nervous system depressant. Exempts all treatments of addiction, chronic intractable pain, medical emergencies, or any situation where the prescriber believes the discussion would be detrimental to the minor's health or safety or in violation of the minor's legal rights regarding confidentiality from the discussion requirements. (HSC § 11158.1)
- Requires a licensed Doctor of Chiropractic to verbally and in writing inform each patient of the material risks of proposed care, defined as a procedure inherently involving known risk of serious bodily harm. The chiropractor shall obtain the patient's written informed consent prior to initiating clinical care. The signed written consent shall become part of the patient's record. A violation of this section constitutes unprofessional conduct and may subject the licensee to disciplinary action. (Title 16, California Code of Regulations, §319.1)
This bill:
- States findings and declarations about the opioid crisis which has prompted an urgent discussion about the risks of addiction associated with overreliance on prescription medication for pain management; a growing body of research indicates that certain nonpharmacological therapies are proven to be equally effective to treat certain causes of pain as prescription opioids, without placing patients at risk for addiction or overdose; to this end, awareness of, and access to, nonpharmacological treatments for pain are vitally important to the state’s efforts to combat the opioid crisis, and that coverage of these treatments should be considered during the next update to the state’s essential health benefits benchmark plan.
- Expands requirements for prescribers in 7) above to discuss risks and dangers of opioids and opioid addiction from only minor patients to all patients.
- Adds a requirement that the prescriber discuss the availability of nonpharmacological treatments for pain.
- Requires the prescriber to obtain written informed consent, that must be placed in the patient’s medical record and that must contain the name and quantity of the controlled substance being prescribed or issued and the amount of the initial dose; a statement certifying that the prescriber discussed the information outlined in 6) above and the availability of nonpharmacological treatments for pain; and that the written informed consent contains space for a signature.
- Requires the prescriber to offer, as deemed appropriate by the prescriber, a referral for a provider of nonpharmacological treatments for pain.
- Specifies that nonpharmacological treatments for pain include, but are not limited to, acupuncture, chiropractic care, physical therapy, occupational therapy, and licensed mental health provider services.
FISCAL EFFECT:
This bill is keyed fiscal by Legislative Counsel. According to the Assembly Committee on Appropriations, this bill will result in minor and absorbable costs to affected boards within the Department of Consumer Affairs for enforcement and for updating regulations, if necessary.
COMMENTS:
- Purpose. This bill is sponsored by the California Chiropractic Association (CalChiro). The Author notes that “According to the California Health Care Foundation, enough opioids are prescribed in a single year in California for every person in the state to medicate themselves around the clock for a month. According to the Centers for Disease Control and Prevention, as many as 50,000 Americans died of an opioid overdose in 2016 – an increase of 28% over the prior year. These death rates exceed those at the height of the AIDS epidemic.”
The Author states that “In the opioid crisis’s broader national context, there has been a persistent perception that California represents a relatively minor segment of an epidemic more typically identified with states like New Hampshire and West Virginia. However, there is substantial evidence that communities in California have been much harder hit than may be generally believed. For example, in 2015, several rural counties in California saw as many or more drug overdose deaths per 100,000 residents than some Midwestern states. It has been reported than some small counties had more opioid prescriptions than residents. In total, the California Department of Public Health estimates that nearly 2,000 Californians died of an opioid overdose in 2016.”
According to the Author, “This bill is intended to increase awareness of, and access to, certain nonpharmacological pain management therapies. Under the bill, this would include acupuncture, chiropractic care, physical therapy, occupational therapy, and behavioral health. These healing arts practices have been shown to be effective in the treatment of pain, but are considered less invasive than pharmacological options and do not pose the same risk of addiction or overdose. While there has been a growing awareness of the risks that come with opioids and other prescription pain medications, patients are rarely made aware of non-opioid treatments for serious pain management needs. Studies have shown that, for many patients, pursuing non-pharmacological therapies can be equally or more effective for treating pain, without the risks of addiction or overdose associated with pharmaceutical painkillers.”
The Author states that “In 2017, the American College of Physicians (ACP) published updated guidelines in the Annals of Internal Medicine, summarizing the results of studies related to the use of noninvasive methods for treating low back pain in adults. In those published guidelines, which followed research involving controlled trials and clinical studies, the ACP wrote that “patients with acute or subacute low back pain usually get better over time, so they probably will not need medicines. They should discuss other treatment options with their doctors.” Specifically, the ACP described studies indicating that effective treatment options include acupuncture, and spinal manipulation. The ACP also describes how studies show that “before taking medicines, patients with chronic low back pain should try other treatments” including “therapy that addresses physical, psychological, and social issues that may be causing pain,” acupuncture, and behavioral health. The ACP states that “opioids should be considered only if no other treatments work and only if there are more benefits than risks for an individual patient.”
The Author cites “additional research and guidance from the CDC in a document titled CDC Guideline for Prescribing Opioids for Chronic Pain, published in the Morbidity and Mortality Weekly Report. According to the Author, “With an intent ‘to improve communication between clinicians and patients about the risks and benefits of opioid therapy,’ the CDC guidelines urge that ‘appropriate use of long-term opioid therapy must be considered within the context of all pain management strategies (including nonopioid pain medications and nonpharmacologic treatments).’ In reviewing the effectiveness of nonpharmacological therapies, the CDC concluded that ‘nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate.”
According to the Author, “This bill would effectively require that in a clinical context where a physician or another prescriber may prescribe an opioid medication for a patient, communication occurs in which the risks of opioids are discussed. Further, the types of nonpharmacological treatments for pain that have clinically demonstrated efficacy with lower associated risks must also be discussed. Following that discussion, the bill does not require that a patient pursue a nonpharmacological approach prior to filling a prescription for opioids; further, a referral must be offered to the patient only as deemed appropriate by the prescriber. The bill does not prohibit or restrict a prescriber’s ability to make recommendations about the appropriateness or potential disadvantages of any such treatment, and an opioid may ultimately still be prescribed without any other therapies being pursued.”
- Background.
Controlled Substances. Through the Controlled Substances Act of 1970, the federal government regulates the manufacture, distribution and dispensing of controlled substances. The act ranks into five schedules those drugs known to have potential for physical or psychological harm, based on three considerations: (a) their potential for abuse; (b) their accepted medical use; and, (c) their accepted safety under medical supervision.
Schedule I controlled substances have a high potential for abuse and no generally accepted medical use such as heroin, ecstasy, and LSD.
Schedule II controlled substances have a currently accepted medical use in treatment, or a currently accepted medical use with severe restrictions, and have a high potential for abuse and psychological or physical dependence. Schedule II drugs can be narcotics or non-narcotic. Examples of Schedule II controlled substances include morphine, methadone, Ritalin, Demerol, Dilaudid, Percocet, Percodan, and Oxycontin.
Schedule III and IV controlled substances have a currently accepted medical use in treatment, less potential for abuse but are known to be mixed in specific ways to achieve a narcotic-like end product. Examples include drugs include Vicodin, Xanax, Ambien and other anti-anxiety drugs.
Schedule V drugs have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.
The three classes of prescription drugs that are most commonly abused are: opioids, which are most often prescribed to treat pain; central nervous system depressants, which are used to treat anxiety and sleep disorders; and stimulants, which are prescribed to treat the sleep disorder narcolepsy and attention-deficit hyperactivity disorder (ADHD). Each class can induce euphoria, and when administered by routes other than recommended, such as snorting or dissolving into liquid to drink or inject, can intensify that sensation.
Opioids, in particular, act on the same receptors as heroin and, therefore, can be highly addictive. Common opioids are: hydrocodone (Vicodin), oxycodone (OxyContin), propoxyphene (Darvon), hydromorphone (Dilaudid), meperidine (Demerol), and diphenoxylate (Lomotil).
Prescription Drug Abuse. For the past number of years, abuse of prescription drugs (taking a prescription medication that is not prescribed for you, or taking it for reasons or in dosages other than as prescribed) to get high has become increasingly prevalent. Results from the 2016 National Survey on Drug Use and Health found that 11.8 million people age 12 or older misused opioids in the past year, the vast majority of whom misused prescription pain relievers. Among people 12 or older who misused pain relievers in the past year, about half (53 percent) indicated that they obtained the last pain relievers they misused from a friend or relative.
The National Institute on Drug Abuse (NIDA) reports young adults (age 18 to 25) are the biggest abusers of prescription opioid pain relievers, ADHD stimulants, and anti-anxiety drugs. In 2014, more than 1,700 young adults died from prescription drug (mainly opioid) overdoses, more than died from overdoses of any other drug, including heroin and cocaine combined, and many more needed emergency treatment. The nonmedical use of prescription drugs is highest among young adults.
Abuse can stem from the fact that prescription drugs are legal and potentially more easily accessible, as they can be found at home in a medicine cabinet. Data shows that individuals who misuse prescription drugs, particularly teens, believe these substances are safer than illicit drugs because they are prescribed by a health care professional and thus are safe to take under any circumstances. NIDA data states that in actuality, prescription drugs act directly or indirectly on the same brain systems affected by illicit drugs, thus, their abuse carries substantial addiction liability and can lead to a variety of other adverse health effects.
Prescription Drug Deaths. According to NIDA, “In 2017, there were 2,199 overdose deaths involving opioids in California—a rate of 5.3 deaths per 100,000 persons, which is lower than the national rate of 14.6 deaths per 100,000 persons. The main driver of drug overdose deaths were those involving prescription opioids with 1,169 deaths in 2017). However, the greatest increase in opioid deaths was seen in cases involving synthetic opioids (mainly fentanyl): a more than twofold increase from 229 to 536 deaths over the past 2-years. Deaths involving heroin also increased in the same period: from 593 in 2012 to 715 deaths in 2017.”
Guidelines for Prescribing Controlled Substances. For certain types of medication, and certain types of medication prescribed to certain types of patients, guidelines on appropriate and safe prescribing practices can serve as a helpful tool for providers, patients and regulatory boards alike. In 1994, the Medical Board of California (MBC) unanimously adopted a policy statement entitled “Prescribing Controlled Substances for Pain.” Stemming from studies and discussions about controlled substances, this policy statement was designed to provide guidance to improve prescriber standards for pain management, while simultaneously undermining opportunities for drug diversion and abuse. The guidelines outlined appropriate steps related to a patient’s examination, treatment plan, informed consent, periodic review, consultation, records, and compliance with controlled substances laws. Subsequent to MBC’s 1994 action, legislation that took effect in 2002 (AB 487, Aroner, Chapter 518, Statutes of 2001) created a task force to revisit the 1994 guidelines to develop standards assuring competent review in cases concerning the under-treatment and under-medication of a patient's pain and also required CE courses for physicians in the subjects of pain management and the treatment of terminally ill and dying patients. The passage of AB 2198 in 2006 (Houston, Chapter 350, Statutes of 2006) updated California law governing the use of drugs to treat pain by clarifying that health care professionals with a medical basis, including the treatment of pain, for prescribing, furnishing, dispensing, or administering dangerous drugs or prescription controlled substances, may do so without being subject to disciplinary action or prosecution.
MBC currently encourages all licensees to consult the policy statement and Guidelines for Prescribing Controlled Substances for Pain which were updated in 2014 based on input from a MBC Prescribing Task Force that held multiple meetings to identify best practices. According to the MBC website, “The board strongly urges physicians and surgeons to view effective pain management as a high priority in all patients, including children, the elderly, and patients who are terminally ill. Pain should be assessed and treated promptly, effectively and for as long as pain persists. The medical management of pain should be based on up-to-date knowledge about pain, pain assessment and pain treatment. Pain treatment may involve the use of several medications and non-pharmacological treatment modalities, often in combination. For some types of pain, the use of medications is emphasized and should be pursued vigorously; for other types, the use of medications is better de-emphasized in favor of other therapeutic modalities. Physicians and surgeons should have sufficient knowledge or utilize consultations to make such judgments for their patients. Medications, in particular opioid analgesics, are considered the cornerstone of treatment for pain associated with trauma, surgery, medical procedures, or cancer.” MBC intends for the guidelines to educate physicians on effective pain management in California by avoiding under treatment, overtreatment, or other inappropriate treatment of a patient’s pain. Reduction of prescription overdose deaths is also an objective of the updated guidelines.
In 2015, the Osteopathic Medical Board of California, which licenses and oversees osteopathic physicians and surgeons, adopted the 2014 MBC guidelines.
NIDA reports, using data from the CDC, that in 2017, “California providers wrote 39.5 opioid prescriptions for every 100 persons. This was among the lowest prescribing rates in the country and significantly lower than the average U.S. rate of 58.7 prescriptions. The rate of overdose deaths involving opioid prescriptions decreased steadily after 2014 to 2.8 deaths per 100,000 persons.”
- Arguments in Support. Supporters believe that this bill will bring awareness to consumers, empower patients with the choice of less invasive options, ensure patients have access to alternative forms of pain management, provide persons recovering from addiction with options they may not be aware exist to help them alleviate pain, and pushes forward the important concept of emphasizing alternatives to opioid usage for pain when appropriate.
According to CalChiro, the Sponsor of this bill, “nonpharmacological treatments, such as chiropractic care is a proven safe, long-term solution to pain that reduces or eliminates the need for opioids and reduces surgical interventions. The Department of Veteran Affairs (VA) has been implementing specific nonpharmacologic therapies recommended by several clinical guidelines…as trained healthcare professionals and longtime advocates of nonpharmacological pain management, we strongly support AB 888’s mission to increase interdisciplinary approaches to the opioid crisis that will facilitate practices that will not only improve health outcomes but also decrease over-reliance on opioids. In order to adequately address the opioid crisis in California we must look at evidenced based treatment options, like non-pharmacological providers, as well as other mechanisms designed to stop opioid addiction in the first place. CalChiro believes this bill will allow multidisciplinary teams to begin working together to find pain management options that will bend the curve on opioid addiction.”
The California Acupuncture and Traditional Medicine Association calls this bill an important, common sense approach to addressing the opioid crisis and further supports the bill for its inclusion of acupuncture as one of the options.
The California Acupuncture Board supports this bill and requests that acupuncture’s other adjunct therapies permitted by an acupuncture license such as Chinese herbal medicine, manual therapy, qi gong, and tai chi “be considered for inclusion of the bill as other nonpharmacological treatments for referral.”
Medtronic supports this bill if it is amended to “include a more complete list of therapies to include interventional procedures and implantable medical device therapies such as [spinal cord stimulation] and [implantable drug delivery systems].”
- Arguments in Opposition. Opponents of AB 888 argue that this measure will create barriers for patients to access necessary pain patients, require unnecessary and unworkable conversations by prescribers, encourage treatments that are not the appropriate standard-of-care in certain situations, and result in numerous referrals to alternative therapies that are often not covered by patients’ health insurers, thus resulting in even higher health care costs on Californians.
The California Chronic Care Coalition opposes AB 888 and considers this bill overreaching and that it will “create more barriers for chronic pain patients to be able to access their pain medications.”
The California Orthopaedic Association argue that AB 888 would create unnecessary and unworkable mandates to offer referrals to treatments that may not be effective, especially for post-surgical pain management, and for treatments often not covered by patients’ health insurance. They note that “[when] orthopaedic surgeons prescribe opioids for pain management, it is often for short-term, post-surgical pain relief. In these situations, nonpharmacological treatments may not give the patient sufficient or any pain relief. It would not be an appropriate standard of care for the patient.”
The California Academy of Family Physicians, the California Medical Association, and the American College of Obstetricians and Gynecologists oppose AB 888 unless amended. They argue that “[despite] the latest amendments allowing the prescriber to determine if a referral is appropriate, the referral mandate is still problematic in that these non-pharmacological services are largely not covered by insurance, and their lack of coverage also means that the providers are not in-network, leaving a physician with few resources in identifying a provider to refer patients to. The bill should, instead, focus on ensuring health plan coverage for these services before mandating that patients be referred to them. When these services are covered, a physician can much more easily determine what providers are covered and in-network for the patient, and can then provide a meaningful and effective referral, when appropriate and with their clinical judgement…
“Physicians are already required to discuss new medications with their patients and the risks and side effects of their medications and treatment plan. AB 888 goes beyond this requirement by dictating what is an appropriate conversation to have about opioids and ignores the specific treatment the opioid is being provided for and the condition of that individual patient.”
California Dental Association opposes this measure unless it is amended to allow a customized and appropriate discussion with patients. They note that this bill “would require dentists to discuss acupuncture or chiropractic services to patients undergoing oral surgery for wisdom teeth extractions, a procedure for which nonpharmacological pain management is not feasible or appropriate.”
Kaiser Permanente also opposes AB 888 unless it is amended to remove the mandated referral to nonpharmacological treatments for pain and the required informed consent. They argue that this bill “dictates the practice of medicine and creates a one-size-fits-all approach which is not in the best interest of our physicians, employees and patients.”
- Drafting Questions, Policy Comments and Amendments.
Written informed consent. There are various areas of the law providing definitions of informed consent, a requirement that carries legal significance and certainly goes beyond mere disclosure. For example:
Judicial Council of California Civil Jury Instruction Number 532:
“Informed Consent—Definition
A patient’s consent to a medical procedure must be “informed.” A patient gives an “informed consent” only after the [insert type of medical practitioner] has adequately explained the proposed treatment or procedure.
[A/An] [insert type of medical practitioner] must explain the likelihood of success and the risks of agreeing to a medical procedure in language that the patient can understand. [A/An] [insert type of medical practitioner] must give the patient as much information as [he/she] needs to make an informed decision, including any risk that a reasonable person would consider important in deciding to have the proposed treatment or procedure, and any other information skilled practitioners would disclose to the patient under the same or similar circumstances. The patient must be told about any risk of death or serious injury or significant potential complications that may occur if the procedure is performed. [A/An] [insert type of medical practitioner] is not required to explain minor risks that are not likely to occur.” (1 CACI 532 (2019))
From the Welfare and Institutions Code:
“For purposes of this chapter, “written informed consent” means that a person knowingly and intelligently, without duress or coercion, clearly and explicitly manifests consent to the proposed therapy to the treating physician and in writing on the standard consent form prescribed in Section 5326.4.” (Welfare and Institutions Code § 5326.5.)
From the Health and Safety Code:
“As used in this chapter, “informed consent” means the authorization given pursuant to Section 24175 to have a medical experiment performed after each of the following conditions have been satisfied:
(a) The subject or subject’s conservator or guardian, or other representative, as specified in Section 24175, is provided with a copy of the experimental subject’s bill of rights, prior to consenting to participate in any medical experiment, containing all the information required by Section 24172, and the copy is signed and dated by the subject or the subject’s conservator or guardian, or other representative, as specified in Section 24175.
(b) A written consent form is signed and dated by the subject or the subject’s conservator or guardian, or other representative, as specified in Section 24175.
(c) The subject or subject’s conservator or guardian, or other representative, as specified in Section 24175, is informed both verbally and within the written consent form, in nontechnical terms and in a language in which the subject or the subject’s conservator or guardian, or other representative, as specified in Section 24175, is fluent, of the following facts of the proposed medical experiment, which might influence the decision to undergo the experiment, including, but not limited to:
(1) An explanation of the procedures to be followed in the medical experiment and any drug or device to be utilized, including the purposes of the procedures, drugs, or devices. If a placebo is to be administered or dispensed to a portion of the subjects involved in a medical experiment, all subjects of the experiment shall be informed of that fact; however, they need not be informed as to whether they will actually be administered or dispensed a placebo.
(2) A description of any attendant discomfort and risks to the subject reasonably to be expected.
(3) An explanation of any benefits to the subject reasonably to be expected, if applicable.
(4) A disclosure of any appropriate alternative procedures, drugs, or devices that might be advantageous to the subject, and their relative risks and benefits.
(5) An estimate of the expected recovery time of the subject after the experiment.
(6) An offer to answer any inquiries concerning the experiment or the procedures involved.
(7) An instruction to the subject that he or she is free to withdraw his or her prior consent to the medical experiment and discontinue participation in the medical experiment at any time, without prejudice to the subject.
(8) The name, institutional affiliation, if any, and address of the person or persons actually performing and primarily responsible for the conduct of the experiment.
(9) The name of the sponsor or funding source, if any, or manufacturer if the experiment involves a drug or device, and the organization, if any, under whose general aegis the experiment is being conducted.
(10) The name, address, and phone number of an impartial third party, not associated with the experiment, to whom the subject may address complaints about the experiment.
(11) The material financial stake or interest, if any, that the investigator or research institution has in the outcome of the medical experiment. For purposes of this section, “material” means ten thousand dollars ($10,000) or more in securities or other assets valued at the date of disclosure, or in relevant cumulative salary or other income, regardless of when it is earned or expected to be earned.
(d) The written consent form is signed and dated by any person other than the subject or the conservator or guardian, or other representative of the subject, as specified in Section 24175, who can attest that the requirements for informed consent to the medical experiment have been satisfied.
(e) Consent is voluntary and freely given by the human subject or the conservator or guardian, or other representative, as specified by Section 24175, without the intervention of any element of force, fraud, deceit, duress, coercion, or undue influence.” (HSC § 24173.)
The Medical Practice Act is fairly limited as to where informed consent is required, with primarily certain major procedures (breast implants, sterilization, breast cancer treatment, IVF and sperm/ova retrieval) establishing this threshold for a prescriber to obtain. Informed consent is also required prior to treating a patient with DMSO, a clear odorless liquid, a by-product of the paper making process, approved by the FDA to treat interstitial cystitis, a bladder health issue which has been the source of research for a number of years and may provide benefit to patients experiencing other medical conditions.
Doctors of chiropractic are required to obtain written informed consent prior to initiating clinical care, a requirement established through regulations promulgated by the Board of Chiropractic Examiners, which is comprised of a majority of practitioners.
Patients should not be required to provide written informed consent prior to their first prescription in a single course of treatment for a controlled substance containing an opioid, as this bill would require, and as such, this requirement should be removed from the bill. The bill should be amended according to the following:
On page 3, in line 17, strike “do both of the following” and replace with “offer, as deemed appropriate by the prescriber, a referral for a provider of nonpharmacological treatments for pain.”
On page 3, strike lines 18-31 inclusive
16
(b) After discussing the information required by subdivision
17
(a), the prescriber shall offer, as deemed appropriate by the prescriber, a referral for a provider of nonpharmacological treatments for pain do both of the following:
18
(1) Obtain informed written consent from the patient, a minor
19
patient’s parent or guardian, or another adult authorized to consent
20
to the minor patient’s medical treatment, which shall be placed in
21
the patient’s medical record and shall contain all of the following:
22
(A) The name and quantity of the controlled substance being
23
prescribed or issued to the patient, and the amount of the initial
24
dose.
25
(B) A statement certifying that the prescriber discussed with
26
the patient, a minor patient’s parent or guardian, or another adult
27
authorized to consent to the minor patient’s medical treatment, the
28
information required by subdivision (a).
29
(C) A space for the signature of the patient, a minor patient’s
30
parent or guardian, or another adult authorized to consent to the
31
minor patient’s medical treatment.
Is it appropriate to statutorily define nonpharmacological treatments for pain? This bill defines “nonpharmacological treatments for pain” as a number of services provided by a number of licensed professionals. Although the bill allows for the inclusion of other treatments with the clause “includes, but is not limited to”, a statutory definition that is neither exhaustive nor data based appears arbitrary and may not be appropriate. Many of the treatments listed in the definition may be effective in pain management but so are a large number of other treatments that are not expressly mentioned in this bill. While the CDC advises the use of nonopioid therapies to the extent possible and suggests nonpharmacological treatments for a variety of conditions that cause chronic pain, the CDC suggests that “Nonpharmacologic therapies and nonopioid medications include: Nonopioid medications such as acetaminophen, ibuprofen, or certain medications that are also used for depression or seizures; Physical treatments (eg, exercise therapy, weight loss); Behavioral treatment (eg, CBT) and ; Interventional treatments (eg, injections).”
Studies are inconclusive as to the efficacy of some of the treatments included in this bill’s definition of nonpharmacological treatments for pain. The National Academies of Science, Engineering, and Medicine conducted a workshop entitled “The Role of Nonpharmacological Approaches to Pain Management” earlier this year where they brought numerous physicians, scientists, and other experts in pain together to discuss alternative pain therapies to opioids. The workshop underlined a lack of evidence supporting the effectiveness of many nonpharmacological pain treatments. Workshop participants discussed a recent study entitled Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review which sought to assess the various noninvasive nonpharmacological treatments for selected chronic pain. The study found limited evidence of the effectiveness of massage therapy, acupuncture, and other interventions in treating low back pain in the short-term, intermediate-term, and long-term.
The bill should be amended to remove a statutory definition for nonpharmacological treatments for pain according to the following:
On page 4, strike lines 5-8 inclusive:
(d) For purposes of this section, “nonpharmacological treatments line 6 for pain” include, but are not limited to, acupuncture, chiropractic line 7 care, physical therapy, occupational therapy, and licensed mental line 8 health provider services.
Should a prescriber be required to offer a referral for nonpharmacological pain treatments? While a referral may be synonymous with a recommendation and may not necessarily require a patient to do anything or seek treatment they are referred for, a referral may also imply more significance than just a simple recommendation from a prescriber. The Author should continue working with prescribers and stakeholders to determine whether the requirement in this bill for a prescriber to offer a referral for nonpharmacological pain treatment is appropriate.
SUPPORT AND OPPOSITION:
Support:
California Chiropractic Association (Sponsor)
Board of Chiropractic Examiners
California Acupuncture and Traditional Medicine Association
California Acupuncture Board
California Consortium of Addiction Programs and Professionals
California Health Coalition Advocacy
California Life Sciences Association
California Physical Therapy Association
County Behavioral Health Directors Association
Independent Physical Therapists of California
Medical Board of California
Medtronic
National Coalition Against Prescription Drug Abuse
Occupational Therapy Association of California
Southern California University of Health Sciences
Opposition:
American Congress of Obstetricians & Gynecologists - District IX
California Academy of Family Physicians
California Chronic Care Coalition
California Dental Association
California Medical Association
California Orthopedic Association
Kaiser Permanente
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 888
Author:(Low)
As Amended Ver:April 11, 2019
Majority vote
SUMMARY:
Extends the requirement for a prescriber to discuss the risks associated with opioids to any adult patients before issuing the first prescription in a single course of treatment for a controlled substance containing an opioid. Exempts a patient currently receiving hospice care from this requirement. Requires the prescriber to discuss the availability of certain nonpharmacological treatments for pain and requires the prescriber to obtain written informed consent and to, if appropriate, offer a referral to a provider of nonpharmacological treatments for pain. Clarifies this bill does not require health care coverage, or change existing health care coverage requirements, for nonpharmacological treatments for pain.
Major Provisions
COMMENTS:
Nonpharmacological Treatments for Pain. This bill is intended to increase awareness of, and access to, certain nonpharmacological pain management therapies. Under this bill, this would include acupuncture, chiropractic care, physical therapy, occupational therapy, and behavioral health. According to the author, these healing arts practices have been shown to be effective in the treatment of pain, but are considered less invasive than pharmacological options and do not pose the same risk of addiction or overdose. In 2017, the American College of Physicians (ACP) published updated guidelines in the Annals of Internal Medicine, summarizing the results of studies related to the use of noninvasive methods for treating low back pain in adults. In those published guidelines, which followed research involving controlled trials and clinical studies, the ACP wrote that "patients with acute or subacute low back pain usually get better over time, so they probably will not need medicines. They should discuss other treatment options with their doctors."
According to the Author:
The California Health Care Foundation (CHCF) has reported that enough opioids are prescribed in a single year in California for every person in the state to medicate themselves around the clock for a month; as many as 50,000 Americans have died of an opioid overdose in a single year. While there has been a growing awareness of the risks that come with opioids and other prescription pain medications, patients are rarely made aware of non-opioid treatments for serious pain management needs. Studies have shown that, for many patients, pursuing non-pharmacological therapies can be equally or more effective for treating pain, without the risks of addiction or overdose associated with pharmaceutical painkillers. As the opioid crisis continues to permeate a national dialogue about the dangers associated with prescription pain medication, this bill would empower patients with the choice of less invasive options while preserving the important relationship between health professionals and their patients.
Arguments in Support:
The California Chiropractic Association (CCA) states that this bill seeks to reduce the over-reliance on prescription opioids by integrating nonpharmacological treatments to pain management care plans and, most importantly, ensures that patients are making well informed decisions before an opioid is prescribed. CCA points to a CHCF report that "states that alternative treatments to opioids, including chiropractic care, have been found to play an important role in the delivery of cost-effective, non-drug services in both acute and chronic stages, as complementary to traditional treatments." In conclusion CCA states that in order to adequately address the opioid crisis in California we must look at evidenced based treatment options, like non-pharmacological providers, as well as other mechanisms designed to stop opioid addiction in the first place.
Arguments in Opposition:
The California Medical Association (CMA) in opposition unless amended states that this bill mandates that a physician obtain written and signed informed consent for every patient who is prescribed an opioid medication. These one-size-fits-all discussions on opioids will now be mandated, and every element of the discussion will be required to be recited, diminishing the value of the discussion completely. CMA states that physicians are already required to discuss new medications with their patients as well as the risks and side effects of their medications and treatment plan. This bill goes beyond this requirement by dictating what is an appropriate conversation to have about opioids and ignores the specific treatment the opioid is being provided for and the condition of that individual patient. CMA concludes by stating it is for this reason that informed consent is not prescribed in statute, but held to the Medical Board of California’s determination for each individual patient and episode of care.
FISCAL COMMENTS:
According to the Assembly Appropriations Committee, this bill has minor and absorbable costs to affected boards within the Department of Consumer Affairs for enforcement and for updating regulations, if necessary (various special funds).
VOTES:
ASM BUSINESS AND PROFESSIONS: 17-0-3
YES: Low, Bloom, Chen, Chiu, Cunningham, Dahle, Fong, Gloria, Grayson, Holden, Irwin, Kamlager-Dove, McCarty, Medina, Mullin, Obernolte, Ting
ABS, ABST OR NV: Brough, Eggman, Gipson
ASM HEALTH: 15-0-0
YES: Wood, Mayes, Aguiar-Curry, Bigelow, Bonta, Burke, Wicks, Flora, Limón, McCarty, Nazarian, Ramos, Rodriguez, Santiago, Waldron
ASM APPROPRIATIONS: 15-0-3
YES: Gonzalez, Bigelow, Bloom, Bonta, Calderon, Carrillo, Chau, Diep, Gabriel, Eduardo Garcia, Maienschein, Obernolte, Petrie-Norris, Jones-Sawyer, Robert Rivas
ABS, ABST OR NV: Brough, Friedman, Fong
UPDATED:
VERSION: April 11, 2019
CONSULTANT: Judith Babcock / HEALTH / (916) 319-2097 FN: 0000337
Date of Hearing: May 1, 2019
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 888
Author:(Low) – As Amended Ver:April 11, 2019
Policy Committee: | Business and Professions | Vote: | 17 - 0 |
Health | 15 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill expands upon current counseling requirements that apply to prescribers writing opioid prescriptions for minors. Specifically, this bill:
- Requires prescribers, in treating patients of any age, to discuss the risks of opioids and the availability of certain nonpharmacological treatments for pain.
- Requires prescribers, in treating patients of any age, to obtain written informed consent from the patient for an opiate prescription and to offer a referral to a provider of nonpharmacological treatments for pain as deemed appropriate by the prescriber.
- Defines nonpharmaclological treatments to include acupuncture, chiropractic care, physicial therapy, occupational therapy and licensed mental health provider services.
FISCAL EFFECT:
Minor and absorbable costs to affected boards within the Department of Consumer Affairs for enforcement and for updating regulations, if necessary (various special funds).
COMMENTS:
- Purpose. According to the author, alternative therapies to treat pain can reduce reliance on opioid drugs and alleviate the opioid epidemic. The author states this bill will empower patients with information and referrals to non-pharmacological therapies studies have shown can be equally or more effective than opioids for treating pain.
- Background. Under the bill, nonpharmaclological treatments would include acupuncture, chiropractic care, physical therapy, occupational therapy and behavioral health.
Federal Centers for Disease Control and Prevention (CDC) guidelines state:
Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate.
- Prior Legislation. SB 1109 (Bates) Chapter 693, Statutes of 2018, requires a prescriber to discuss the with a minor, or the minor’s parent, guardian or other adult authorized to consent to the minor’s medical treatment, information relating to the risks associated with opioids prior to dispensing or issuing a prescription of opioids to a minor for the first time.
- Support and Opposition. The California Chiropractic Association (CCA), the sponsor of this bill, states it seeks to reduce the over-reliance on prescription opioids and ensure patients make informed choices. Physical therapy and acupuncture advocacy groups also support this bill. The California Medical Association (CMA) states in opposition that the requirement a physician obtain written and signed informed consent for every patient who is prescribed an opioid medication imposes unnecessary administrative hurdles.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: April 9, 2019
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 888
Author:(Low) – As Amended Ver:March 21, 2019
SUBJECT: Opioid prescriptions: information: nonpharmacological treatments for pain.
SUMMARY: Extends the requirement for a prescriber to discuss the risks associated with opioids to any adult patients before issuing the first prescription in a single course of treatment for a controlled substance containing an opioid. Exempts a patient currently receiving hospice care from this requirement. Requires the prescriber to discuss the availability of certain nonpharmacological treatments for pain and requires the prescriber to obtain written informed consent and to offer a referral to a provider of nonpharmacological treatments for pain. Specifically, this bill:
- Requires a prescriber to discuss information regarding the risks association with opioids to a patient before issuing the first prescription in a single course of treatment for a controlled substance containing an opioid.
- Exempts a patient currently receiving hospice care from 1) above. Removes the current exemption from 1) above for a diagnosis of chronic intractable pain.
- Requires a prescriber to discuss the availability of nonpharmaclological treatments defined to include acupuncture, chiropractic care, physicial therapy, occupational therapy, and licensed mental health provider services.
- Requires the prescriber after discussing the required information to do both of the following:
- Obtain informed written consent from the patient, a minor patient’s parent or guardian, or another adult authorized to consent to the minor patient’s medical treatment, which is to be placed in the patient’s medical record and to contain all of the following:
- The name and quanitity of the controlled substance being prescribed or issued to the patient, and the amount of the initial dose;
- A statement certifying that the prescriber discussed with the patient, a minor patient’s parent or guardian, or another adult authorized to consent to the minor patient’s medical treatment, the required information; and,
- A space for the signature of the patient, a minor patient’s parent or guardian or another adult authorized to consent to the minor patient’s medical treatment.
- Requires the prescriber to offer a referral for a provider of nonpharmacological treatments for pain.
- Obtain informed written consent from the patient, a minor patient’s parent or guardian, or another adult authorized to consent to the minor patient’s medical treatment, which is to be placed in the patient’s medical record and to contain all of the following:
- Makes legislative findings and declarations relating to addiction associated with overreliance on prescription medication for pain management, and providing that nonpharmacological treatments for pain should be considered during the next update to the state’s essential health benefits benchmark plan.
EXISTING LAW:
- Allows a physician, dentist, podiatrist, veterinarian, naturopathic doctor, registered nurse, certified nurse-midwife, optometrist, or out-of-state prescriber to write or issue a prescription.
- Requires a prescription for a controlled substance to be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of their professional practice, and that the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription.
- Prohibits medical professionals from prescribing, administering, or dispensing a controlled substance to an addict, as defined.
- Requires a prescriber to discuss the following with a minor, or the minor’s parent, guardian, or other adult authorized to consent to the minor’s medical treatment, prior to dispensing or issuing a prescription of opioids to a minor for the first time:
- The risks of addiction and overdose associated with the use of opioids;
- The increased risk of addiction to an opioid to an individual who is suffering from both mental and substance abuse disorders;
- The danger of taking an opioid with a benzodiazepine, alcohol, or another central nervous system depressant; and,
- Any other information required by law.
- Requires certain health care practitioners beginning October 2, 2018, to consult the Controlled Substance Utilization Review and Evaluation System (CURES) database to review a patient’s controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions.
FISCAL EFFECT: This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, the California Health Care Foundation (CHCF)has reported that enough opioids are prescribed in a single year in California for every person in the state to medicate themselves around the clock for a month; as many as 50,000 Americans have died of an opioid overdose in a single year. While there has been a growing awareness of the risks that come with opioids and other prescription pain medications, patients are rarely made aware of non-opioid treatments for serious pain management needs. Studies have shown that, for many patients, pursuing non-pharmacological therapies can be equally or more effective for treating pain, without the risks of addiction or overdose associated with pharmaceutical painkillers. This would recognize the expansive body of research into the efficacy of less invasive treatments for pain that do not pose the same serious risks as opioid medication. As the opioid crisis continues to permeate a national dialogue about the dangers associated with prescription pain medication, this bill would empower patients with the choice of less invasive options while preserving the important relationship between health professionals and their patients.
- BACKGROUND.
- Overview of the Opioid Crisis. In October of 2017, the White House declared the opioid crisis a public health emergency, formally recognizing what had long been understood to be a growing epidemic responsible for devastation in communities across the country. According to the Centers for Disease Control and Prevention (CDC), as many as 50,000 Americans died of an opioid overdose in 2016, representing a 28% increase over the previous year. Additionally, the number of Americans who died of an overdose of fentanyl and other opioids more than doubled during that time with nearly 20,000 deaths. These death rates compare to, and potentially exceed, those at the height of the AIDS epidemic.
Opioids are a class of drugs prescribed and administered by health professionals to manage pain. Modern use of the term “opioid” typically describes both naturally occurring opiates derived from the opium poppy as well as their manufactured synthetics. Common examples of prescription opioids include oxycodone (OxyContin, Percocet); hydrocodone (Vicodin, Norco, Lorcet); codeine; morphine; and fentanyl. Heroin is also an opioid.
In addition to providing pain relief, opioids can be used as a cough suppressant, an antidiarrheal, a method of sedation, and a treatment for shortness of breath. The majority of pharmaceutical opioids are Schedule II drugs under the federal Controlled Substances Act, considered by the federal Drug Enforcement Agency (DEA) to have a high potential for abuse that may lead to severe psychological or physical dependence. However, combination drugs containing lower doses of opioids combined with other active ingredients are typically less restricted; for example, cough syrups containing low doses of codeine are frequently classified Schedule V medications.
The abuse of prescription drugs was historically viewed as a criminal concern analogous to street narcotics cases regularly investigated by law enforcement. In recent years, however, an expert consensus has evolved around the opinion that the opioid crisis must be addressed through the lens of public health policy. This belief is supported by research demonstrating how health professionals may have inadvertently contributed to the origins of the crisis. It is widely accepted that health professionals will play a critical role in any meaningful solutions.
In the opioid crisis’s broader national context, there has been a persistent perception that California represents a relatively minor segment of an epidemic more typically identified with states like New Hampshire and West Virginia. However, there is substantial evidence that communities in California have been hit much harder than may be generally believed. For example, in 2015, several rural counties in California saw as many or more drug overdose deaths per 100,000 residents than some Midwestern states. It has been reported than some small counties had more opioid prescriptions than residents. In 2018 the Department of Public Health (DPH) reported 2,196 opioid overdose deaths in California with 4,281 emergency department (ED) visits for all opioids (excluding heroin). Deaths as a result of fentanyl increased to 429 in 2018, up from 237 in 2016.
- Nonpharmacological Treatments for Pain. This bill is intended to increase awareness of, and access to, certain nonpharmacological pain management therapies. Under the bill, this would include acupuncture, chiropractic care, physical therapy, occupational therapy, and behavioral health. According to the author, these healing arts practices have been shown to be effective in the treatment of pain, but are considered less invasive than pharmacological options and do not pose the same risk of addiction or overdose.
In 2017, the American College of Physicians (ACP) published updated guidelines in the Annals of Internal Medicine, summarizing the results of studies related to the use of noninvasive methods for treating low back pain in adults. In those published guidelines, which followed research involving controlled trials and clinical studies, the ACP wrote that “patients with acute or subacute low back pain usually get better over time, so they probably will not need medicines. They should discuss other treatment options with their doctors.” Specifically, the ACP described studies indicating that effective treatment options include acupuncture, and spinal manipulation. The ACP also describes how studies show that “before taking medicines, patients with chronic low back pain should try other treatments” including “therapy that addresses physical, psychological, and social issues that may be causing pain,” acupuncture, and behavioral health. The ACP states that “opioids should be considered only if no other treatments work and only if there are more benefits than risks for an individual patient.”
- CDC Guidelines. Additional research and guidance has come from the CDC in a document titled “CDC Guideline for Prescribing Opioids for Chronic Pain”, published in the Morbidity and Mortality Weekly Report. With an intent “to improve communication between clinicians and patients about the risks and benefits of opioid therapy,” the CDC guidelines urge that “appropriate use of long-term opioid therapy must be considered within the context of all pain management strategies (including nonopioid pain medications and nonpharmacologic treatments).” In reviewing the effectiveness of nonpharmacological therapies, the CDC concluded that “nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate.”
This bill would require that in a clinical context where a physician or another prescriber may prescribe an opioid medication for a patient, communication occurs on the risks of opioids. Further, the types of nonpharmacological treatments for pain that have clinically demonstrated efficacy with lower associated risks must also be discussed. Following that discussion, the bill does not require that a patient pursue a nonpharmacological approach prior to filling a prescription for opioids; however, a referral must be offered to the patient. This bill does not prohibit or restrict a prescriber’s ability to make recommendations about the appropriateness or potential disadvantages of any such treatment, and an opioid may ultimately still be prescribed without any other therapies being pursued.
- SUPPORT. The California Chiropractic Association (CCA), sponsor of this bill states that this bill seeks to reduce the over-reliance on prescription opioids by integrating nonpharmacological treatments to pain management care plans and, most importantly, ensures that patients are making well informed decisions before an opioid is prescribed. CCA points to a CHCF report that “states that alternative treatments to opioids, including chiropractic care, have been found to play an important role in the delivery of cost-effective, non-drug services in both acute and chronic stages, as complementary to traditional treatments.” In conclusion CCA states that in order to adequately address the opioid crisis in California we must look at evidenced based treatment options, like non-pharmacological providers, as well as other mechanisms designed to stop opioid addiction in the first place.
The Occupational Therapy Association of California also in support of this bill, states that in 2016 there were 2,012 opioid-related overdose deaths in California. This bill is another important step to change the conversations surrounding pain management. Nonpharmacological pain management includes several different ways to alter thoughts and focus concentration to better manage and reduce pain, including occupational therapy.
- OPPOSITION. The California Medical Association (CMA) in opposition states that this bill mandates that a physician obtain written and signed informed consent for every patient who is prescribed an opioid medication. This is a further unnecessary administrative hurdle for physicians who are already constantly handed more and more forms to have signed, disclosures to give, discussions to have, and other impediments to providing the most appropriate care for their patient. These one-size-fits-all discussions on opioids will now be mandated, and every element of the discussion will be required to be recited, diminishing the value of the discussion completely. CMA states that physicians are already required to discuss new medications with their patients as well as the risks and side effects of their medications and treatment plan. This bill goes beyond this requirement by dictating what is an appropriate conversation to have about opioids and ignores the specific treatment the opioid is being provided for and the condition of that individual patient. CMA concludes by stating it is for this reason that informed consent is not prescribed in statute, but held to the Medical Board of California’s determination for each individual patient and episode of care.
- RELATED LEGISLATION.
- AB 528 (Low) would change the requirement for pharmacists to report dispensed prescriptions from seven days to the following business day. AB 526 is pending in the Assembly Business and Professions Committee.
- AB 387 (Gabriel) would require a physician and surgeon to indicate the purpose for a drug or device on the prescription for that drug or device when providing a prescription to a patient unless the patient chooses to opt out of having the purpose for the drug or device included on the prescription. AB 378 is pending in the Assembly Business and Professions Committee.
- PREVIOUS LEGISLATION.
- AB 2487 (McCarty), Chapter 301, Statutes of 2018, authorizes a physician, as an alternative to the mandatory course on pain management, to complete a one-time continuing education course of 12 credit hours in the subjects of treatment and management of opiate-dependent patients, including eight hours of training in buprenorphine treatment, or other similar medicinal treatment, for opioid use disorders.
- AB 2741 (Burke) of 2018 would have limited all opioid prescriptions for minors to a maximum of five days, with exceptions, and require a prescriber to discuss risks related to opioid medication with the minor and the minor’s parent or guardian and obtain verbal consent prior to writing the prescription. AB 2741 failed passage in the Senate Business, Professions, and Economic Development Committee
- SB 1109 (Bates) Chapter 693, Statutes of 2018, requires a prescriber to discuss the following with a minor, or the minor’s parent, guardian, or other adult authorized to consent to the minor’s medical treatment, information relating to the risks associated with opioids prior to dispensing or issuing a prescription of opioids to a minor for the first time.
- DOUBLE REFERRAL. This bill has been double referred. It passed the Assembly Business and Professions Committee with a vote 17-3 on April 3, 2019.
- COMMITTEE AMENDMENTS.
- Referral to a nonpharmacological provider. As written, the bill is unclear as to whether the referral to a provider of nonpharmacological treatments for pain is mandatory or optional. The author has agreed to amend this bill to state that a referral of a patient to a provider of nonpharmacological treatments for pain occurs as deemed appropriate by a prescriber.
- Nonpharmacological treatment. The author has agreed to amend this bill to include a provision that this bill is not to be construed as requiring or mandating healthcare coverage for nonpharmacological treatments for pain.
REGISTERED SUPPORT / OPPOSITION:
Support
California Chiropractic Association (sponsor)
California Acupuncture and Traditional Medicine Association
California Health Coalition Advocacy
Independent Physical Therapists of California
Occupational Therapy Association of California
Opposition
California Medical Association
Analysis Prepared by: Judith Babcock / HEALTH / (916) 319-2097
Date of Hearing:
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Evan Low, Chair
ABPCA Bill Id:AB 888
Author:(Low) – As Amended Ver:March 21, 2019
SUBJECT: Opioid prescriptions: information: nonpharmacological treatments for pain.
SUMMARY: Extends current requirements for a prescriber to discuss the risks associated with opioids with their patient prior to issuing a first prescription for an opioid and additionally directs that information about the availability of certain nonpharmacological treatments for pain be provided, along with an offer for a referral.
EXISTING LAW:
- Allows only a physician, dentist, podiatrist, veterinarian, naturopathic doctor, registered nurse, certified nurse-midwife, optometrist, or out-of-state prescriber to write or issue a prescription. (Health and Safety Code Section (HSC) § 11150)
- States that a prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of their professional practice, and that the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. (HSC § 11153)
- Prohibits medical professionals from prescribing, administering, or dispensing a controlled substance to an addict, as defined. (HSC § 11156)
- Requires a prescriber to discuss the following with a minor, or the minor’s parent, guardian, or other adult authorized to consent to the minor’s medical treatment, prior to dispensing or issuing a prescription of opioids to a minor for the first time:
- The risks of addiction and overdose associated with the use of opioids.
- The increased risk of addiction to an opioid to an individual who is suffering from both mental and substance abuse disorders.
- The danger of taking an opioid with a benzodiazepine, alcohol, or another central nervous system depressant.
- Any other information required by law.
(HSC § 11158.1)
- Beginning October 2, 2018, requires certain health care practitioners to consult the Controlled Substance Utilization Review and Evaluation System (CURES) database to review a patient’s controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions. (HSC § 11165.4)
THIS BILL:
- Extends the requirement that a prescriber discuss information regarding the risks of opioids when prescribing opioids to a minor patient to apply to patients of any age.
- Requires that the discussion requirement be memorialized through informed written consent from the patient, a minor patient’s parent or guardian, or another authorized adult.
- Adds information about the availability of nonpharmacological treatments for pain to the discussion requirements, defined as including acupuncture, chiropractic care, physical therapy, occupational therapy, and licensed mental health provider services.
- Following the discussion, requires a prescriber to offer a referral for a provider of nonpharmacological treatments for pain.
- Makes legislative findings and declarations relating to addiction associated with overreliance on prescription medication for pain management, and providing that nonpharmacological treatments for pain should be considered during the next update to the state’s essential health benefits benchmark plan.
FISCAL EFFECT: Unknown; this bill is keyed fiscal by the Legislative Counsel.
COMMENTS:
Purpose. This bill is sponsored by the California Chiropractic Association. The author states:
According to the California Health Care Foundation, enough opioids are prescribed in a single year in California for every person in the state to medicate themselves around the clock for a month; as many as 50,000 Americans have died of an opioid overdose in a single year. While there has been a growing awareness of the risks that come with opioids and other prescription pain medications, patients are rarely made aware of non-opioid treatments for serious pain management needs. Studies have shown that, for many patients, pursuing non-pharmacological therapies can be equally or more effective for treating pain, without the risks of addiction or overdose associated with pharmaceutical painkillers. AB 888 would recognize the expansive body of research into the efficacy of less invasive treatments for pain that do not pose the same serious risks as opioid medication. As the opioid crisis continues to permeate a national dialogue about the dangers associated with prescription pain medication, AB 888 would empower patients with the choice of less invasive options while preserving the important relationship between health professionals and their patients.
Background.
Overview of the Opioid Crisis. In October of 2017, the White House declared the opioid crisis a public health emergency, formally recognizing what had long been understood to be a growing epidemic responsible for devastation in communities across the country. According to the Centers for Disease Control and Prevention (CDC), as many as 50,000 Americans died of an opioid overdose in 2016, representing a 28 percent increase over the previous year. Additionally, the number of Americans who died of an overdose of fentanyl and other opioids more than doubled during that time with nearly 20,000 deaths. These death rates compare to, and potentially exceed, those at the height of the AIDS epidemic.
Opioids are a class of drugs prescribed and administered by health professionals to manage pain. Modern use of the term “opioid” typically describes both naturally occurring opiates derived from the opium poppy as well as their manufactured synthetics. Common examples of prescription opioids include oxycodone (OxyContin, Percocet); hydrocodone (Vicodin, Norco, Lorcet); codeine; morphine; and fentanyl. Heroin is also an opioid.
In addition to providing pain relief, opioids can be used as a cough suppressant, an antidiarrheal, a method of sedation, and a treatment for shortness of breath. The majority of pharmaceutical opioids are Schedule II drugs under the federal Controlled Substances Act, considered by the federal Drug Enforcement Agency (DEA) to have a high potential for abuse that may lead to severe psychological or physical dependence. However, combination drugs containing lower doses of opioids combined with other active ingredients are typically less restricted; for example, cough syrups containing low doses of codeine are frequently classified Schedule V medications.
The abuse of prescription drugs was historically viewed as a criminal concern analogous to street narcotics cases regularly investigated by law enforcement. In recent years, however, an expert consensus has evolved around the opinion that the opioid crisis must be addressed through the lens of public health policy. This belief is supported by research demonstrating how health professionals may have inadvertently contributed to the origins of the crisis. It is widely accepted that health professionals will play a critical role in any meaningful solutions.
In the opioid crisis’s broader national context, there has been a persistent perception that California represents a relatively minor segment of an epidemic more typically identified with states like New Hampshire and West Virginia. However, there is substantial evidence that communities in California have been much harder hit than may be generally believed. For example, in 2015, several rural counties in California saw as many or more drug overdose deaths per 100,000 residents than some Midwestern states. It has been reported than some small counties had more opioid prescriptions than residents. In total, the California Department of Public Health estimates that nearly 2,000 Californians died of an opioid overdose in 2016.
Nonpharmacological Treatments for Pain. This bill is intended to increase awareness of, and access to, certain nonpharmacological pain management therapies. Under the bill, this would include acupuncture, chiropractic care, physical therapy, occupational therapy, and behavioral health. These healing arts practices have been shown to be effective in the treatment of pain, but are considered less invasive than pharmacological options and do not pose the same risk of addiction or overdose.
In 2017, the American College of Physicians (ACP) published updated guidelines in the Annals of Internal Medicine, summarizing the results of studies related to the use of noninvasive methods for treating low back pain in adults. In those published guidelines, which followed research involving controlled trials and clinical studies, the ACP wrote that “patients with acute or subacute low back pain usually get better over time, so they probably will not need medicines. They should discuss other treatment options with their doctors.” Specifically, the ACP described studies indicating that effective treatment options include acupuncture, and spinal manipulation. The ACP also describes how studies show that “before taking medicines, patients with chronic low back pain should try other treatments” including “therapy that addresses physical, psychological, and social issues that may be causing pain,” acupuncture, and behavioral health. The ACP states that “opioids should be considered only if no other treatments work and only if there are more benefits than risks for an individual patient.”
Additional research and guidance has come from the CDC in a document titled CDC Guideline for Prescribing Opioids for Chronic Pain, published in the Morbidity and Mortality Weekly Report. With an intent “to improve communication between clinicians and patients about the risks and benefits of opioid therapy,” the CDC guidelines urge that “appropriate use of long-term opioid therapy must be considered within the context of all pain management strategies (including nonopioid pain medications and nonpharmacologic treatments).” In reviewing the effectiveness of nonpharmacological therapies, the CDC concluded that “nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate.”
This bill would effectively require that in a clinical context where a physician or another prescriber may prescribe an opioid medication for a patient, communication occurs in which the risks of opioids are discussed. Further, the types of nonpharmacological treatments for pain that have clinically demonstrated efficacy with lower associated risks must also be discussed. Following that discussion, the bill does not require that a patient pursue a nonpharmacological approach prior to filling a prescription for opioids; however, a referral must be offered to the patient. The bill does not prohibit or restrict a prescriber’s ability to make recommendations about the appropriateness or potential disadvantages of any such treatment, and an opioid may ultimately still be prescribed without any other therapies being pursued.
Current Related Legislation. AB 528 (Low) would change the requirement for pharmacists to report dispensed prescriptions from seven days to the following business day. This bill is pending in the Assembly Business and Professions Committee.
AB 387 (Gabriel) would require a physician and surgeon to indicate the purpose for a drug or device on the prescription for that drug or device when providing a prescription to a patient unless the patient chooses to opt out of having the purpose for the drug or device included on the prescription. This bill is pending in the Assembly Business and Professions Committee.
Prior Related Legislation. SB 1109 (Bates, Chapter 693, Statutes of 2018) requires a prescriber to discuss the following with a minor, or the minor’s parent, guardian, or other adult authorized to consent to the minor’s medical treatment, information relating to the risks associated with opioids prior to dispensing or issuing a prescription of opioids to a minor for the first time.
ARGUMENTS IN SUPPORT:
The California Chiropractic Association (CalChiro) is sponsoring this bill. CalChiro explains that the bill “seeks to reduce the over-reliance on prescription opioids by integrating nonpharmacological treatments to pain management care plans and, most importantly, ensures that patients are making well informed decisions before an opioid is prescribed.” CalChiro points to a California Health Care Foundation report that “states that alternative treatments to opioids, including chiropractic care, have been found to play an important role in the delivery of cost-effective, non-drug services in both acute and chronic stages, as complementary to traditional treatments.” CalChiro states that “in order to adequately address the opioid crisis in California we must look at evidenced based treatment options, like non-pharmacological providers, as well as other mechanisms designed to stop opioid addiction in the first place. CalChiro believes this bill will allow multidisciplinary teams to begin working together to find pain management options that will bend the curve on opioid addiction.”
The California Acupuncture and Traditional Medicine Association (CalATMA) also supports this bill. According to CalATMA, this bill “is an important, common sense approach to addressing the opioid crisis. In 2018, the Joint Commission updated with pain management standards to require hospitals seeking accreditation to provide nonpharmacological pain treatment modalities, noting they should ‘promote nonpharmacologic modalities by ensuring that patient preferences are discussed and, at a minimum, providing some nonpharmacologic treatment options relevant to their patient population.’ We further support AB 888 for its inclusion of acupuncture as one of the options. The efficacy of acupuncture for pain management is well-known, and it is recommended by the American College of Physicians as a first-line treatment for lower-back pain.”
The Occupational Therapy Association of California (OTAC) also supports the bill. According to OTAC, “according to the California Department of Public Health, in 2016 there were 2,012 opioid-related overdose deaths in California, a rate of 4.9 deaths per 100,000 persons. California has taken several important steps to tackling the opioid crisis. AB 888 is another important step to change the conversations surrounding pain management. Non-pharmacological pain management includes several different ways to alter thoughts and focus concentration to better manage and reduce pain, including occupational therapy.”
The Independent Physical Therapists of California (IPT) supports the bill. IPT argues that “AB 888 tackles one of the most sensitive and ubiquitous issues possible; the treatment ofchronic pain. The road to this point is strewn with tragic consequences as well as well-managed triumphs. Notwithstanding the now-common repugnance to over used opioid based therapy, our medical profession along with others, realizes there is not a one-sizefits- all solution. AB 888 not only correctly identifies the doctor/patient relationship as the centerpiece of any pain management decision but goes further to explore how best to bring a team approach to that decision.” IPT states that it “applauds AB 888 as it represents a critical step along the path of developing that sound team approach and helping decide under what circumstances, which members of the team are on the court.”
ARGUMENTS IN OPPOSITION:
None on file.
REGISTERED SUPPORT:
California Chiropractic Association (Sponsor)
California Acupuncture and Traditional Medicine Association
California Health Coalition Advocacy
Independent Physical Therapists of California
Occupational Therapy Association of California
REGISTERED OPPOSITION:
None on file.
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301
Bill Author
Bill Co-Author(s):